Drew Ranieri
Stock Analyst at Morgan Stanley
(1.19)
# 3,685
Out of 4,984 analysts
167
Total ratings
44.44%
Success rate
-12.61%
Average return
Main Sectors:
Stocks Rated by Drew Ranieri
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMED Globus Medical | Maintains: Overweight | $75 → $68 | $56.22 | +20.95% | 13 | Jul 15, 2025 | |
| ORGO Organogenesis Holdings | Maintains: Equal-Weight | $4 → $6 | $4.62 | +29.87% | 4 | Mar 5, 2025 | |
| ATEC Alphatec Holdings | Assumes: Equal-Weight | $9.5 → $10 | $14.70 | -31.97% | 10 | Dec 2, 2024 | |
| SYK Stryker | Upgrades: Overweight | $370 → $445 | $376.88 | +18.07% | 9 | Dec 2, 2024 | |
| SIBN SI-BONE | Maintains: Overweight | $21 → $19 | $14.71 | +29.16% | 15 | Aug 6, 2024 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $27 | $14.80 | +82.43% | 15 | Jul 15, 2024 | |
| TMCI Treace Medical Concepts | Maintains: Equal-Weight | $5.5 → $8 | $7.04 | +13.64% | 12 | Jul 15, 2024 | |
| STVN Stevanato Group | Maintains: Equal-Weight | $26 → $22 | $26.93 | -18.31% | 16 | Jul 15, 2024 | |
| NPCE NeuroPace | Maintains: Equal-Weight | $9.5 → $8 | $9.89 | -19.11% | 13 | Jul 15, 2024 | |
| OM Outset Medical | Maintains: Equal-Weight | $75 → $83 | $13.93 | +492.25% | 10 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 → $38 | $20.98 | +81.12% | 9 | Nov 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $88 → $96 | $49.95 | +92.19% | 10 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $28 → $26 | $11.86 | +119.22% | 8 | May 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $290 → $295 | $187.57 | +57.27% | 2 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $236 → $280 | $125.62 | +122.89% | 5 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $5 | $6.93 | -27.85% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $70 | $23.20 | +201.72% | 4 | Oct 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $325 → $300 | $433.66 | -30.82% | 6 | Apr 25, 2022 |
Globus Medical
Jul 15, 2025
Maintains: Overweight
Price Target: $75 → $68
Current: $56.22
Upside: +20.95%
Organogenesis Holdings
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $4 → $6
Current: $4.62
Upside: +29.87%
Alphatec Holdings
Dec 2, 2024
Assumes: Equal-Weight
Price Target: $9.5 → $10
Current: $14.70
Upside: -31.97%
Stryker
Dec 2, 2024
Upgrades: Overweight
Price Target: $370 → $445
Current: $376.88
Upside: +18.07%
SI-BONE
Aug 6, 2024
Maintains: Overweight
Price Target: $21 → $19
Current: $14.71
Upside: +29.16%
Integra LifeSciences Holdings
Jul 15, 2024
Maintains: Underweight
Price Target: $24 → $27
Current: $14.80
Upside: +82.43%
Treace Medical Concepts
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $5.5 → $8
Current: $7.04
Upside: +13.64%
Stevanato Group
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $26 → $22
Current: $26.93
Upside: -18.31%
NeuroPace
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $9.5 → $8
Current: $9.89
Upside: -19.11%
Outset Medical
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $75 → $83
Current: $13.93
Upside: +492.25%
Nov 2, 2023
Maintains: Overweight
Price Target: $42 → $38
Current: $20.98
Upside: +81.12%
May 12, 2023
Maintains: Equal-Weight
Price Target: $88 → $96
Current: $49.95
Upside: +92.19%
May 4, 2023
Maintains: Underweight
Price Target: $28 → $26
Current: $11.86
Upside: +119.22%
Feb 3, 2023
Maintains: Overweight
Price Target: $290 → $295
Current: $187.57
Upside: +57.27%
Jan 6, 2023
Maintains: Equal-Weight
Price Target: $236 → $280
Current: $125.62
Upside: +122.89%
Nov 10, 2022
Maintains: Overweight
Price Target: $11 → $5
Current: $6.93
Upside: -27.85%
Oct 11, 2022
Maintains: Overweight
Price Target: $72 → $70
Current: $23.20
Upside: +201.72%
Apr 25, 2022
Maintains: Equal-Weight
Price Target: $325 → $300
Current: $433.66
Upside: -30.82%